Physician profile
Mark E Leary
NPI 1083755763
$7,038.57
in general payments reported to CMS, 2019-2025
22 companies · $2,617 in 2025
The $2,617 reported for 2025 was more than what 98% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $724 · 2020: $279 · 2021: $641 · 2022: $487 · 2023: $437 · 2024: $1,853 · 2025: $2,617.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,398 · Travel and Lodging: $1,494 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,000 · Entertainment: $14.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,398.22 |
| Travel and Lodging | $1,493.94 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,000.00 |
| Entertainment | $14.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,953.65 | 2019-2025 | Total30, Dailies Total1, Precision 1 |
| Coopervision INC. | $1,919.72 | 2019-2025 | Cvi Contact Lens, Biofinity Contact Lens, Myday Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $892.43 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $828.51 | 2022-2025 | Infuse, Miebo, Xiidra |
| Notal Vision, INC. | $285.18 | 2024-2025 | Foresee Home |
| Sun Pharmaceutical Industries INC. | $273.30 | 2019-2025 | Cequa |
| Tarsus Pharmaceuticals, INC. | $176.37 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $158.77 | 2019-2023 | |
| Oyster Point Pharma, INC. | $90.43 | 2022-2024 | Tyrvaya, Ryzumvi |
| Dompe US, INC. | $67.64 | 2022-2025 | Oxervate |
| Allergan, INC. | $59.09 | 2019-2021 | |
| Abbvie INC. | $47.61 | 2022-2024 | |
| Thea Pharma INC. | $47.56 | 2023 | |
| Staar Surgical Company | $38.87 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $36.43 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $31.35 | 2019 | |
| Kala Pharmaceuticals, INC. | $30.07 | 2021-2022 | |
| Harrow Eye, LLC | $25.93 | 2024 | Vevye |
| Sight Sciences, INC. | $24.47 | 2019 | |
| Glaukos Corporation | $23.25 | 2024 | Radius |
| Optos, INC. | $14.81 | 2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Aerie Pharmaceuticals, INC. | $13.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Leary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.